Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® , Rituxan® , and Herceptin® that collectively represented...
Read More »
Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration approval for Provenge® , the first active immunotherapy approved for the treatment of cancer in the U.S. Today, shares of Dendreon traded as low as $28.01,...
Read More »
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of...
Read More »
Approximately 250 million people worldwide have been diagnosed with diabetes mellitus and that number is growing with the increasing obesity population. Broadly, patients with diabetes are characterized by elevated blood glucose levels that result from either insufficient insulin secretion (type-1 diabetes) or ineffective insulin action (type-2 diabetes). The market for treating patients with diabetes...
Read More »
